Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 8/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 4/20 | 0.55 |
| ▸ | TP53 | P04637 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16136100 | 0.89 | KDM4E (0.67) | KDM4EGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL16136046 | 0.85 | KDM4E (0.74) | KDM4EGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL16135907 | 0.85 | KDM4E (0.74) | KDM4EGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL16311057 | 0.85 | KDM4E (0.77) | KDM4EGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL16136101 | 0.84 | KDM4E (0.75) | KDM4EGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL16136161 | 0.84 | KDM4E (0.69) | KDM4EGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL16136105 | 0.84 | KDM4E (0.72) | KDM4EGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL16136045 | 0.84 | KDM4E (0.66) | KDM4EGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL16135901 | 0.83 | KDM4E (0.68) | KDM4EGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL16136103 | 0.83 | KDM4E (0.95) | KDM4EGAAMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370366-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2019-08-06 | — | — | US | disclosed |
| US-10370366-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180093976-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2018-04-05 | — | — | US | disclosed |
| US-20180093976-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2018-04-05 | — | — | US | disclosed |
| US-20180093976-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2018-04-05 | — | — | US | disclosed |
| US-9790215-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790215-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790215-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-9783529-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783529-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783529-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2017-10-10 | — | — | US | disclosed |
| US-20150005300-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005300-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005300-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140371225-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140371225-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140371225-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-12-18 | — | — | US | disclosed |
| WO-2014160440-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005300-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC26A4, PNPO | KDM4E 3610/4885GAA 771/4885MAPT 4861/4885 |
| US-20180093976-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC26A4, PNPO | KDM4E 3610/4885GAA 771/4885MAPT 4861/4885 |
| US-20140371225-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, NDUFB7, NDUFB5 | KDM4E 4123/4885GAA 581/4885MAPT 4864/4885 |
| US-10370366-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | CFTR, SLC26A4, PNPO | KDM4E 3610/4885GAA 771/4885MAPT 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.